Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer

Drug Delivery

Volumn 23, Issue 4, 2016, Pages 1232-1241

  Doddapaneni, Ravi ^a   Patel, Ketan ^a   Owaid, Ibtisam Hasan ^b   Singh, Mandip ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; cationic liposome; enhanced permeation and retention; gambogic acid; triple negative breast cancer

Indexed keywords

CD31 ANTIGEN; CYCLIN D1; DOCETAXEL; GAMBOGIC ACID; LIPOSOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SURVIVIN; ANTINEOPLASTIC AGENT; CATION; MACROGOL DERIVATIVE; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG RELEASE; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HEPG2 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ZETA POTENTIAL; BREAST NEOPLASMS; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG SCREENING; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATIONS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; TRIPLE NEGATIVE BREAST NEOPLASMS; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951279788     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1124472     Document Type: Article

References (34)

1. G.Adlakha-Hutcheon, M.B.Bally, C.R.Shew, T.D.Madden (1999). Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol 17:775–9
2. F.André, C.C.Zielinski (2012). Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23:vi46–51
3. E.Andreopoulou, S.J.Schweber, J.A.Sparano, H.M.McDaid (2015). Therapies for triple negative breast cancer. Expert Opin Pharmacother 16:983–98
4. M.Bonotto, L.Gerratana, E.Poletto,. (2014). Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 19:608–15
5. 2000 micelles. Int J Nanomedicine 9:243–55
6. H.I.Chang, M.K.Yeh (2012). Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49–60
7. P.P.Deshpande, S.Biswas, V.P.Torchilin (2013). Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 8:1509–28
8. R.Doddapaneni, Y.K.Chawla, A.Das,. (2013). Overexpression of microRNA-122 enhances in vitro hepatic differentiation of fetal liver-derived stem/progenitor cells. J Cell Biochem 114:1575–83
9. C.Godugu, A.R.Patel, R.Doddapaneni,. (2014). Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One 9:e89919
10. H.Gu, S.Rao, J.Zhao,. (2009). Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 135:1777–82
11. M.L.Immordino, F.Dosio, L.Cattel (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297–315
12. C.Li, N.Lu, Q.Qi,. (2011). Gambogic acid inhibits tumor cell adhesion by suppressing integrin β1 and membrane lipid rafts-associated integrin signaling pathway. Biochem Pharmacol 82:1873–83
13. C.Li, Q.Qi, N.Lu,. (2012). Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol 90:718–30
14. Y.T.Liu, K.Hao, X.Q.Liu, G.J.Wang (2006). Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin 27:1253–8
15. N.Lu, H.Hui, H.Yang,. (2013). Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway. Eur J Pharm Sci 49:220–6
16. N.Lu, Y.Yang, Q.D.You,. (2007). Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett 258:80–9
17. G.Misso, M.T.Di Martino, G.De Rosa,. (2014). Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids 3:e194. doi: 10.1038/mtna.2014.47
18. R.Naithani, L.C.Huma, R.M.Moriarty,. (2008). Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15:1044–71
19. J.R.Palmer, E.Viscidi, M.A.Troester,. (2014). Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst 106:237. doi: 10.1093/jnci/dju237
20. K.Patel, A.Patil, M.Mehta,. (2013). Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol. J Biomed Nanotechnol 9:1996–2006
21. K.Patel, A.Patil, M.Mehta,. (2014). Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. Int J Pharm 472:214–23
22. W.O.Pereira, G.P.Amarante-Mendes (2011). Apoptosis: a programme of cell death or cell disposal? Scand J Immunol 73:401–7
23. Q.Qi, H.Gu, Y.Yang,. (2008a). Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med (Berl) 86:1367–77
24. Q.Qi, Q.You, H.Gu,. (2008b). Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol 117:433–8
25. R.R.Sawant, V.P.Torchilin (2012). Challenges in development of targeted liposomal therapeutics. AAPS J 14:303–15
26. V.Saxena, M.D.Hussain (2012). Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer. Int J Nanomedicine 7:713–21
27. Z.Tao, A.Shi, C.Lu,. (2014). Breast cancer: epidemiology and etiology. Cell Biochem Biophys 72:333–8
28. A.V.Vaseva, U.M.Moll (2009). The mitochondrial p53 pathway. Biochim Biophys Acta 1787:414–20
29. X.Wang, W.Chen (2012). Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem 12:994–1000
30. M.Xing, F.Yan, S.Yu, P.Shen (2015). Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials. PLoS One 10:e0133569. doi: 10.1371/journal.pone.0133569
31. J.Xu, M.Zhou, J.Ouyang,. (2013). Gambogic acid induces mitochondria-dependent apoptosis by modulation of Bcl-2 and Bax in mantle cell lymphoma JeKo-1 cells. Chin J Cancer Res 25:183–91
32. J.Yao, Y.Li, X.Sun,. (2014). Nanoparticle delivery and combination therapy of gambogic acid and all-trans retinoic acid. Int J Nanomedicine 9:3313–24
33. D.Zhai, C.Jin, C.W.Shiau,. (2008). Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 7:1639–46
34. Z.Y.Zou, J.Wei, X.L.Li,. (2012). Enhancement of anticancer efficacy of chemotherapeutics by gambogic acid against gastric cancer cells. Cancer Biother Radiopharm 27:299–306